Long Term Extension Study is Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection

Inclusion Criteria: \- Participated in Study SPC3649-205 (this would include those who completed study SPC3649-205, those who discontinued or terminated the study early for whatever reason (including treatment failure) and those who opted to receive approved therapy for the treatment of HCV infection). Exclusion Criteria: * Those unwilling to provide informed consent for participation in this study. * Subjects who have received investigational drug therapy after discontinuation, termination, or successful completion of Study SPC3649-205.